RESEARKA

The evidence base for angiotensin receptor blockers (ARBs) and longevity is derived from indirect sources, including a systematic review and meta-analysis on heart failure therapies (Wang 2026), observational cohort studies on medication adherence (Murray-Thomas 2025) and guideline-directed medical therapy (Jin 2025), and a pilot trial protocol for a polypill strategy (Agarwal 2025). No direct, randomized controlled trials isolating ARB monotherapy for a primary longevity endpoint were identified within this curated corpus. The population examined across these studies is adults with cardiovascular conditions such as heart failure or acute coronary syndrome, with outcomes typically assessed over hospital or follow-up periods rather than lifespan durations (Jin 2025; Murray-Thomas 2025). The primary endpoint across the relevant studies is mortality, encompassing in-hospital death and all-cause mortality linked to medication use (Jin 2025; Murray-Thomas 2025). The dosing of ARBs in these contexts is part of broader guideline-directed medical therapy regimens, not evaluated in isolation for longevity effects (Agarwal 2025; Jin 2025).

Citation Support

• source_1 Solomon 2026
• source_2 Din 2026
• source_3 Li 2025
• source_4 Mei 2025
• source_5 Chung 2024